Company Overview - LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease, which affects over 200 million people globally [3] - The company develops, manufactures, and markets both disposable and implantable vascular devices aimed at vascular surgeons [3] Financial Results Announcement - LeMaitre Vascular will release its second quarter 2025 financial results on August 5, 2025, after market close [1] - A conference call is scheduled for 5:00 PM EDT on the same day to discuss the financial results, business highlights, and company outlook [1] Access to Conference Call - Access to the live conference call requires online registration, after which registrants will receive dial-in information and a PIN [2] - The audio webcast will be available live and for replay through the company's investor relations website [2]

Key Takeaways VEEV rose nearly 29% in three months, driven by strong Q1 results. VEEV's Vault CRM has over 80 customers, with plans to more than double that number by the end of 2026. VEEV to launch AI tools like CRM Bot, as Crossix and CRM Pulse see rising adoption among pharma clients.Veeva Systems (VEEV) has been on a strong upswing, with its stock climbing nearly 29% over the past three months. The rally followed the company’s solid earnings for the first quarter of fiscal 2026, where revenues came in ...

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks with the highest potential to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E, PEG, and Price/Sales to find attractive investment opportunities [3] - The Growth Score assesses a company's financial health and future outlook by analyzing projected and historical earnings, sales, and cash flow to identify stocks with sustainable growth potential [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes, emphasizing the importance of following market trends [5] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for investors who utilize multiple investment strategies [6] Zacks Rank and Style Scores Integration - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to assist investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7][8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 that also have Style Scores of A or B, while stocks with a 3 (Hold) rank should also possess high Style Scores to ensure potential upside [9][10] Company Spotlight: Universal Health Services (UHS) - Universal Health Services Inc. operates various healthcare facilities and currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of B, indicating potential for growth [11] - Recent analyst revisions have positively impacted UHS's earnings estimates for fiscal 2025, with the Zacks Consensus Estimate rising by $0.19 to $19.43 per share, alongside an average earnings surprise of 13.8% [12]

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Gilead Sciences (GILD) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Gilead Sciences is a member of the Medical sector. This group includes 987 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 16 different sector groups. ...

Core Insights - Hologic (HOLX) is currently attractively priced with a Value Score of B, trading at a forward five-year price-to-sales (P/S) of 3.39X, which is lower than its median of 4.33X and the industry average of 4.14X [1][4] - The company has faced a tough macroeconomic environment, resulting in a 10.8% year-to-date decline in shares, underperforming the industry and S&P 500 [5] - Despite returning to top-line growth in Q3 of fiscal 2024, fiscal 2025 has shown mixed performance with a 0.9% revenue increase in Q1 and a 1.2% decline in Q2 [7][10] Valuation Comparison - Hologic's P/S ratio of 3.39X is favorable compared to peers QIAGEN (3.30X) and Abbott (2.50X), but it trades at a premium to the broader Medical sector's historical average of 2.33X [4] - The company has reaffirmed its revenue guidance but lowered its adjusted EPS forecast to $4.15-$4.25 from $4.25-$4.35, indicating potential challenges ahead [12] Performance Challenges - Hologic's performance has been impacted by a stronger U.S. dollar, a significant drop in Breast Health revenues, and the loss of a $50 million annual revenue stream from HIV testing in Africa [8][10] - Analysts have become increasingly cautious, with the Zacks Consensus Estimate for fiscal 2025 EPS decreasing by 2.1% to $4.19 over the past 90 days [13] Growth Drivers - The Surgical business has shown a 7.6% compound annual growth rate (CAGR) over the last decade, driven by products like MyoSure and the acquisition of Gynesonics [15] - Hologic's strong financial health is highlighted by $169.5 million in operating cash generated in Q2 of fiscal 2025 and a cash position of $1.43 billion [16] Overall Outlook - While Hologic's Surgical division shows ongoing momentum and financial stability, macroeconomic headwinds and declining sales in key areas have negatively impacted performance [17] - The negative earnings estimate trend suggests continued near-term challenges, leading to a less compelling investment case at this time [18]

Core Insights - Intuitive Surgical (ISRG) has achieved a 15% year-over-year increase in da Vinci system installations, surpassing 10,000 units globally, with 367 systems placed in Q1 2025, including 147 next-gen da Vinci 5 systems, driven by strong U.S. demand [1][10] - Recurring revenues constitute 85% of total revenues, with overall procedures growing 17% year-over-year; however, average system utilization increased only 2%, indicating a potential issue with return on investment for hospitals [2][3] - The limited growth in core platform utilization raises concerns about hospital ROI post-installation, prompting management to focus on training and digital adoption to enhance throughput [3][4] Competitive Landscape - Stryker (SYK) reported record Mako installations in Q1 2025, driven by strong demand in orthopedics, with high utilization rates particularly in knee and hip procedures [5] - Stryker plans to launch Mako Spine later in 2025 and Mako Shoulder in early 2026, aiming to expand its robotic offerings across specialties [6] - Zimmer Biomet's (ZBH) ROSA robotics platform is seeing ongoing adoption in knee procedures, although results are more muted compared to competitors; the system is central to ZBH's robotic strategy for 2025 [7][8] Financial Performance - ISRG shares have gained 2.4% year-to-date, contrasting with a 7.7% decline in the industry [9] - The forward price-to-earnings ratio for ISRG stands at 64.35, above the industry average but lower than its five-year median of 72.21, with a Value Score of D [12] - The Zacks Consensus Estimate for ISRG's 2025 earnings suggests a 6.8% increase from the previous year [13]

Core Viewpoint - Medtronic plc has appointed Chad Spooner as the chief financial officer (CFO) of MiniMed, ahead of its planned separation into a standalone public company, effective July 14, 2025 [1][5]. Company Overview - Medtronic is a global leader in healthcare technology, headquartered in Galway, Ireland, with a mission to alleviate pain, restore health, and extend life [8]. - The company employs over 95,000 people across more than 150 countries and addresses 70 health conditions through various technologies and therapies [8]. Leadership Appointment - Chad Spooner brings over 25 years of financial leadership experience in healthcare, consumer, and industrial sectors, previously serving as CFO at BIC and holding senior finance roles at General Electric and other companies [2][4]. - His appointment is seen as crucial for driving transformation and growth as MiniMed prepares for independence [3][4]. MiniMed Separation - Medtronic announced that MiniMed will be the name of the new standalone company, honoring its 40-year legacy in diabetes care [3]. - The separation is expected to be completed within 18 months of the initial announcement, subject to customary conditions and legal requirements [5]. Mission and Vision - MiniMed's mission is to make diabetes management more predictable, enhancing the lives of individuals with diabetes through advanced technology and support [7].

Leading Endovascular Innovators to Highlight Emergence and Growth of Robotics in the SpecialtyHINGHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announced its participation in the inaugural Endovascular Robotics session at the Society of Robotic Surgery (SRS) annual meeting, being held from July 16-20, in Strasbourg, France. The Company applauds the SRS for recognizing the growing need to spotlight this fi ...

RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants from warrant holders on June 30, 2025. The repurchase was completed as part of the Company’s capital formation strategy and reflects its continued confidence in its product development of a long-te ...

Core Insights - SeaStar Medical Holding Corporation has introduced QUELIMMUNE therapy at Texas Children's Hospital, which is a potential life-saving treatment for pediatric patients with acute kidney injury (AKI) due to sepsis [1][2] - The QUELIMMUNE therapy has shown a 77% survival rate compared to standard care, indicating a 50% reduction in loss of life in this patient population [1][4] - The therapy is designed to neutralize over-active immune cells and mitigate hyperinflammation, which is critical in treating AKI [2][8] Company Overview - SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure [9] - The QUELIMMUNE therapy is the only FDA-approved product for life-threatening AKI in critically ill pediatric patients [9] - The company has received Breakthrough Device Designation for six therapeutic indications, facilitating a faster approval process [9] Clinical Data and Trials - Clinical data published in Kidney Medicine supports the efficacy of QUELIMMUNE, showing no dialysis required for survivors at Day 60 post-ICU discharge [1][6] - SeaStar Medical is conducting the NEUTRALIZE-AKI pivotal trial to evaluate the safety and efficacy of SCD therapy in adults with AKI [3][7] - The primary endpoint of the NEUTRALIZE-AKI trial includes a composite of 90-day mortality or dialysis dependency [7] Market Impact - The introduction of QUELIMMUNE addresses a significant unmet need for organ-sparing therapies in pediatric patients [2] - The therapy aims to reduce healthcare costs associated with prolonged ICU stays and reliance on dialysis [3] - SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its contributions to pediatric AKI treatment [6]